Glioma–astrocyte connexin43 confers temozolomide resistance through activation of the E2F1/ERCC1 axis
Our study reveals a novel regulatory mechanism in which the Cx43/miR-205-5p/E2F1/ERCC1 axis contributes to TMZ resistance in glioma. These findings further highlight the potential of targeting Cx43 as a therapeutic strategy in glioma.
Authors
- Di Pan (ORCID: https://orcid.org/0000-0003-1825-8838)
- Xiangshan Fan (ORCID: https://orcid.org/0000-0003-4552-5858)
- Jieying Zhou
- Hongkun Qin
- Yuting Ye (ORCID: https://orcid.org/0000-0003-2643-7457)
- Fangyu Ye (ORCID: https://orcid.org/0000-0002-5780-1680)
- Yanping Gui (ORCID: https://orcid.org/0000-0001-9209-8452)
- Qianqian Chen (ORCID: https://orcid.org/0000-0002-5838-2991)
- Li Zhao (ORCID: https://orcid.org/0000-0003-1576-8787)
- Tian Geng (ORCID: https://orcid.org/0000-0001-5877-5560)
- Xinyu Zhang (ORCID: https://orcid.org/0000-0002-6492-6270)
- Shihe Yang
- Yajing Wang (ORCID: https://orcid.org/0000-0002-3605-8437)
Institutions
- Guiyang Medical University (CN)
- China Pharmaceutical University (CN)
- Florida International University (US)
- Nanjing Drum Tower Hospital (CN)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1093/neuonc/noae237
- Citations
- 7
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.07